High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer

Breast Cancer Research

Table 2 Log-rank, univariate and multivariate associations with OS for clinical variables and genomic characteristics for 176 primary HER2+ tumors

Investigated covariate^a	Number tumors	Log-rank P	Univariate P	Multivariate P ^b
ER+ vs. ER-	64/112	0.96	0.96	0.79
LN+ vs. LN-	110/65	4 × 10^-6 ***	9 × 10^-6 ***	0.0002***
Size >20 mm vs. ≤ 20 mm	122/49	0.002**	0.002**	0.02*
Histological grade 3 vs. 1 and 2	37/26	0.91	0.91	0.83
Age <50 vs. ≥50 years	73/103	0.22	0.23	0.77
DNA Aneuploid vs. Diploid	106/37	0.001**	0.001**	0.005**
DNA Aneuploid vs. Diploid ER+	37/11	0.008**	0.02*	0.07
DNA Aneuploid vs. Diploid ER-	69/26	0.05*	0.05*	0.06
Recurrent 17q amplification, yes vs. no	70/106	0.17	0.17	0.13
Recurrent amplification excluding 17q, yes vs. no	76/100	0.75	0.75	0.7
Firestorm pattern, yes vs. no	78/98	0.27	0.28	0.58
High FGA vs. low FGA^c	42/46	0.08	0.09	0.25
High FGA vs. low FGA ER+ tumors^c	18/17	0.09	0.09	0.26
High FGA vs. low FGA ER- tumors^c	24/29	0.37	0.37	0.55

^a Variables with worst outcome highlighted in bold for covariates significantly associated with OS.^b Multivariate analysis included LN status and stratified tumor size besides the tested covariate.^c High and Low FGA defined as >75^th percentile and <25^th percentile of all FGA values respectively.
*: Significant at P < 0.05
**: Significant at P < 0.01
***: Significant at P < 0.001

ISSN: 1465-542X